Myomo (MYO) Stock Forecast & Price Target

Myomo is positioned for attractive fundamental growth because Q2 2026 revenue rose 21% year over year to $11.7 million, above both estimates and guidance, while EPS of $(0.09) beat expectations, signaling improving operating leverage as commercialization scales. The company’s core catalyst is the March 2024 Medicare Part B reimbursement expansion, which materially enlarges the addressable market for MyoPro and is already translating into stronger U.S. O&P demand, with that channel up 130% year over year in Q2 and 100% in 2025. With 211 units sold, a 1,491 reimbursement pipeline, raised 2026 revenue guidance of $45 million to $47 million, and expanding international revenue, Myomo appears to be converting a large market opportunity into sustained top-line momentum.

Myomo is facing a fundamentally fragile outlook because its business depends on financing stability, regulatory continuity, and successful commercialization of a specialized medical device, any of which could undermine growth. Its revenue model is also exposed to reimbursement uncertainty, since it bills insurance companies directly and relies on suitable coverage and, at times, paid clinical services from orthotics and prosthetics providers, while competing in a niche medtech market with shifting consumer and government healthcare priorities. These risks are compounded by balance sheet and liquidity concerns, plus macroeconomic and sentiment-driven pressure on biotech and medtech stocks, which can restrict capital access and weaken execution even if the MyoPro remains FDA-registered as a Class II device.